Once-daily Adderall XR receives approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Once-daily formulation of Shire's attention deficit hyperactivity disorder therapy Adderall is approved Oct. 11. Adderall XR will be the third once-daily ADHD agent on the market, joining Johnson & Johnson's Concerta and Celltech's Metadate CD. Adderall XR labeling states that patients taking immediate-release Adderall may be switched to "Adderall XR at the same total daily dose taken once-daily"